Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate.
Infliximab is a tumour necrosis factor (TNF)-alpha blocking drug classified as a biological response modifier. It has been suggested that the risk of malignancies, especially lymphomas, is increased in patients with rheumatoid arthritis (RA) treated with anti-TNF-alpha antibody therapy. We present a case of malignant lymphoma during the treatment of RA with infliximab and methotrexate.
Nakashima
C
C
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tanioka
M
M
Takahashi
K
K
Miyachi
Y
Y
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004344:Drug Incompatibility; D005260:Female; D006801:Humans; D000069285:Infliximab; D008113:Liver Neoplasms / Q000556:secondary; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced* / Q000175:diagnosis; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D035441:Thoracic Wall; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D008727:Methotrexate